Chemical Property of 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one
Chemical Property:
- Appearance/Colour:White crystalline solid
- Vapor Pressure:5.81E-18mmHg at 25°C
- Melting Point:275-277 °C
- Refractive Index:1.748
- Boiling Point:653.4 °C at 760 mmHg
- PKA:14.42±0.10(Predicted)
- Flash Point:348.9 °C
- PSA：130.05000
- Density:1.68 g/cm3
- LogP:-0.72610
- Storage Temp.:-20°C Freezer
- Solubility.:0.02 M potassium phosphate: soluble2mg/mL
- Purity/Quality:
-
99%min *data from raw suppliers
Penciclovir *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xi
- Hazard Codes:Xi
- Statements:
36
- Safety Statements:
26
- MSDS Files:
-
SDS file from LookChem
Useful:
-
Description
Vectavir was launched in the UK for herpes labialis. Penciclovir is
synthetically available by two routes of four steps each from 2-
(hydroxymethyl)butane-l,4-diol and is active against HSV-1, HSV-2 VZV but has
limited activity against CMV. Vectavir is an acyclic guanosine analog that acts as a
competitive inhibitor of DNA polymerase. It is a metabolic product of famcyclovir that
is preferentially phosphorylated by viral infected cells (by thymidine kinases) over
normal cells. The triphosphate has a low activity against cellular DNA polymerase
which is one possible explanation for its low toxicity. While its spectrum of activity is
similar to acyclovir, it is longer acting because its triphosphate is 20 times more
stable and is not metabolized.
-
Uses
An antiviral. A deuterated version of Penciclovir, an antiviral
-
Indications
Penciclovir has activity against HSV-1, HSV-2,
VZV, and HBV. After oral administration, famciclovir is
converted to penciclovir by first-pass metabolism.
Penciclovir has a mechanism of action similar to that of
acyclovir. It is first monophosphorylated by viral thymidine
kinase; then it is converted to a triphosphate by
cellular kinases.
-
Therapeutic Function
Antiviral
-
Clinical Use
Herpes zoster and genital herpes
Orolabial herpes (topical) Penciclovir is approved as a topical formulation for the
treatment of herpes labialis. In immunocompetent individuals,
penciclovir shortens the duration of lesion presence
and pain by approximately half a day when it is initiated
within an hour of lesion development and applied
every 2 hours during waking hours for 4 days.
